Condition: Breast Neoplasms · Brain Neoplasms · Neoplasms by Site · Sponsor: Stemline Therapeutics, Inc.
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose (RP2D) and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in participants with active brain metastases from ER-positive, HER-2 negative breast cancer.
This description comes directly from the study's public registry record.
Stemline Trials · 1-877-332-7961 · clinicaltrials@menarinistemline.com
Always discuss trial participation with your own doctor first.
| Providence Medical Foundation | Fullerton, California, United States | Recruiting |
| California Research Institute | Los Angeles, California, United States | Recruiting |
| Carle Cancer Center | Urbana, Illinois, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Henry Ford Hospital | Detroit, Michigan, United States | Recruiting |
| Miami Valley Hospital South | Centerville, Ohio, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Completed |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| UT Health San Antonio University of Texas | San Antonio, Texas, United States | Completed |
| Virginia Cancer Institute | Norfolk, Virginia, United States | Recruiting |
| Antwerp University Hospital | Edegem, Belgium | Recruiting |
+ 74 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05386108